Position in LLY
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$512,156
+$128,612 QoQ
Shares Held
427
+2.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
#3,739
of 4,605 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Pine Haven Investment Counsel, Inc holds $11,878,503 across 7 Drug Manufacturers - General names. LLY ranks #5 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
17,973 | $4,522,725 | |
| 2 | AMGN |
Amgen Inc
|
6,341 | $2,296,202 | |
| 3 | JNJ |
Johnson & Johnson
|
8,955 | $2,274,301 | |
| 4 | MRK |
Merck & Co., Inc.
|
14,273 | $1,834,080 | |
| 5 | LLY |
ELI LILLY & Co
This page
|
427 | $512,156 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
1,851 | $233,855 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,561 | $205,184 |
All Filings in LLY
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $512,156 | 427 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $383,544 | 417 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $448,141 | 417 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $313,593 | 411 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $316,489 | 406 | Shares | Sole | 2025-07-15 | |
| 2025-03-31 | $330,364 | 400 | Shares | Sole | 2025-04-11 | |
| 2024-12-31 | $308,800 | 400 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $354,376 | 400 | Shares | Sole | 2024-10-09 | |
| 2024-06-30 | $362,152 | 400 | Shares | Sole | 2024-07-12 | |
| 2024-03-31 | $311,184 | 400 | Shares | Sole | 2024-04-25 | |
| 2023-12-31 | $233,168 | 400 | Shares | Sole | 2024-01-22 | |
| 2023-09-30 | $214,852 | 400 | Shares | Sole | 2023-11-06 | |
| No filing history on record for this holder in this stock. | ||||||